Novel epigenetic changes in CDKN2A are associated with progression of cervical intraepithelial neoplasia

Gynecologic Oncology

Volumn 142, Issue 3, 2016, Pages 566-573

  Wijetunga, N Ari ^a   Belbin, Thomas J ^a,b   Burk, Robert D ^a   Whitney, Kathleen ^a   Abadi, Maria ^a   Greally, John M ^a   Einstein, Mark H ^a,c   Schlecht, Nicolas F ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Biomarker; Cervical cancer; CIN; Methylation; p14; p16

Indexed keywords

BISULFITE; GENOMIC DNA; CDK2AP2 PROTEIN, HUMAN; CDKN2A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2C; ONCOPROTEIN; P16 PROTEIN, HUMAN;

ADULT; AGED; APC GENE; ARTICLE; CANCER GROWTH; CDH1 GENE; CDH13 GENE; CDKN2A GENE; CDKN2B GENE; CONTROLLED STUDY; CPG ISLAND; DAPK1 GENE; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; FEMALE; FHIT GENE; GENE LOCUS; GENE MAPPING; GENETIC TRANSCRIPTION; GSTP1 GENE; HIC1 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MGMT GENE; MLH1 GENE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RARB GENE; RASSF1 GENE; TERT GENE; TIMP3 GENE; TUMOR INVASION; TUMOR SUPPRESSOR GENE; UNIVARIATE ANALYSIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; BIOSYNTHESIS; DISEASE COURSE; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; UTERINE CERVIX TUMOR; YOUNG ADULT;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P18; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENES, P16; GENES, TUMOR SUPPRESSOR; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84990223865     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.07.006     Document Type: Article

References (52)

1. [1] Clifford, G.M., Smith, J.S., Plummer, M., Munoz, N., Franceschi, S., Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88 (2003), 63–73.
2. [2] Bosch, F.X., de Sanjose, S., Chapter 1: human papillomavirus and cervical cancer–burden and assessment of causality. J. Natl. Cancer Inst. Monogr., 3-13, 2003.
3. [3] Khan, M.J., Castle, P.E., Lorincz, A.T., Wacholder, S., Sherman, M., Scott, D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97 (2005), 1072–1079.
4. [4] Castle, P.E., Solomon, D., Schiffman, M., Wheeler, C.M., Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J. Natl. Cancer Inst. 97 (2005), 1066–1071.
5. [5] Cuzick, J., Thomas Cox, J., Zhang, G., Einstein, M.H., Stoler, M., Trupin, S., et al. Human papillomavirus testing for triage of women with low-grade squamous intraepithelial lesions. Int. J. Cancer 132 (2013), 959–966.
6. [6] Wentzensen, N., Sherman, M.E., Schiffman, M., Wang, S.S., Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol. Oncol. 112 (2009), 293–299.
7. [7] Banzai, C., Nishino, K., Quan, J., Yoshihara, K., Sekine, M., Yahata, T., et al. Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma. Int. J. Clin. Oncol. 19 (2014), 127–132.
8. [8] Lai, H.C., Lin, Y.W., Huang, T.H., Yan, P., Huang, R.L., Wang, H.C., et al. Identification of novel DNA methylation markers in cervical cancer. Int. J. Cancer 123 (2008), 161–167.
9. [9] Wang, S.S., Smiraglia, D.J., Wu, Y.Z., Ghosh, S., Rader, J.S., Cho, K.R., et al. Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning. Cancer Res. 68 (2008), 2489–2497.
10. [10] Shivapurkar, N., Sherman, M.E., Stastny, V., Echebiri, C., Rader, J.S., Nayar, R., et al. Evaluation of candidate methylation markers to detect cervical neoplasia. Gynecol. Oncol. 107 (2007), 549–553.
11. [11] Louvanto, K., Franco, E.L., Ramanakumar, A.V., Vasiljevic, N., Scibior-Bentkowska, D., Koushik, A., et al. Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. Int. J. Cancer 136 (2015), E638–E645.
12. [12] Litjens, R.J., Hopman, A.H., van de Vijver, K.K., Ramaekers, F.C., Kruitwagen, R.F., Kruse, A.J., Molecular biomarkers in cervical cancer diagnosis: a critical appraisal. Expert Opin. Med. Diagn. 7 (2013), 365–377.
13. [13] Gil, J., Peters, G., Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat. Rev. Mol. Cell Biol. 7 (2006), 667–677.
14. [14] Paschos, K., Allday, M.J., Epigenetic reprogramming of host genes in viral and microbial pathogenesis. Trends Microbiol. 18 (2010), 439–447.
15. [15] Jha, A.K., Nikbakht, M., Jain, V., Capalash, N., Kaur, J., p16(INK4a) and p15(INK4b) gene promoter methylation in cervical cancer patients. Oncol. Lett. 3 (2012), 1331–1335.
16. [16] Lof-Ohlin, Z.M., Levanat, S., Sabol, M., Sorbe, B., Nilsson, T.K., Promoter methylation in the PTCH gene in cervical epithelial cancer and ovarian cancer tissue as studied by eight novel pyrosequencing(R) assays. Int. J. Oncol. 38 (2011), 685–692.
17. [17] Huang, L.W., Pan, H.S., Lin, Y.H., Seow, K.M., Chen, H.J., Hwang, J.L., P16 methylation is an early event in cervical carcinogenesis. Int. J. Gynecol. Cancer 21 (2011), 452–456.
18. [18] Furtado, Y.L., Almeida, G., Lattario, F., Silva, K.S., Maldonado, P., Silveira, F.A., et al. The presence of methylation of the p16INK4A gene and human papillomavirus in high-grade cervical squamous intraepithelial lesions. Diagn. Mol. Pathol. 19 (2010), 15–19.
19. [19] Kim, J.H., Choi, Y.D., Lee, J.S., Lee, J.H., Nam, J.H., Choi, C., Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. Gynecol. Oncol. 116 (2010), 99–104.
20. [20] Burk, R.D., Kadish, A.S., Calderin, S., Romney, S.L., Human papillomavirus infection of the cervix detected by cervicovaginal lavage and molecular hybridization: correlation with biopsy results and Papanicolaou smear. Am. J. Obstet. Gynecol. 154 (1986), 982–989.
21. [21] Darragh, T.M., Colgan, T.J., Thomas Cox, J., Heller, D.S., Henry, M.R., Luff, R.D., et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int. J. Gynecol. Pathol. 32 (2013), 76–115.
22. [22] Mancuso, F.M., Montfort, M., Carreras, A., Alibes, A., Roma, G., HumMeth27QCReport: an R package for quality control and primary analysis of Illumina Infinium methylation data. BMC Res. Notes, 4, 2011, 546.
23. [23] Suzuki, M., Jing, Q., Lia, D., Pascual, M., McLellan, A., Greally, J.M., Optimized design and data analysis of tag-based cytosine methylation assays. Genome Biol., 11, 2010, R36.
24. [24] Ulahannan, N., Greally, J.M., Genome-wide assays that identify and quantify modified cytosines in human disease studies. Epigenetics Chromatin, 8, 2015, 5.
25. [25] McLellan, A.S., Dubin, R.A., Jing, Q., Broin, P.O., Moskowitz, D., Suzuki, M., et al. The wasp system: an open source environment for managing and analyzing genomic data. Genomics 100 (2012), 345–351.
26. [26] Li, L.C., Dahiya, R., MethPrimer: designing primers for methylation PCRs. Bioinformatics 18 (2002), 1427–1431.
27. [27] Tusnady, G.E., Simon, I., Varadi, A., Aranyi, T., BiSearch: primer-design and search tool for PCR on bisulfite-treated genomes. Nucleic Acids Res., 33, 2005, e9.
28. [28] Qu, W., Jiang, G., Cruz, Y., Chang, C.J., Ho, G.Y., Klein, R.S., et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5 +/GP6 + primer systems. J. Clin. Microbiol. 35 (1997), 1304–1310.
29. [29] Castle, P.E., Schiffman, M., Gravitt, P.E., Kendall, H., Fishman, S., Dong, H., et al. Comparisons of HPV DNA detection by MY09/11 PCR methods. J. Med. Virol. 68 (2002), 417–423.
30. [30] Clifford, G.M., Gallus, S., Herrero, R., Munoz, N., Snijders, P.J., Vaccarella, S., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366 (2005), 991–998.
31. [31] del Refugio Gonzalez-Losa, M., Laviada Mier y Teran, M.A., Puerto-Solis, M., Garcia-Carranca, A., Molecular variants of HPV type 16 E6 among Mexican women with LSIL and invasive cancer. J. Clin. Virol. 29 (2004), 95–98.
32. [32] Tukey, J.W., Exploratory Data Analysis. 1977, Addison–Wesley, Reading, MA.
33. [33] Maldonado, G., Greenland, S., Estimating causal effects. Int. J. Epidemiol. 31 (2002), 422–438.
34. [34] Virmani, A.K., Muller, C., Rathi, A., Zoechbauer-Mueller, S., Mathis, M., Gazdar, A.F., Aberrant methylation during cervical carcinogenesis. Clin. Cancer Res. 7 (2001), 584–589.
35. [35] Dong, S.M., Kim, H.S., Rha, S.H., Sidransky, D., Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin. Cancer Res. 7 (2001), 1982–1986.
36. [36] Narayan, G., Arias-Pulido, H., Koul, S., Vargas, H., Zhang, F.F., Villella, J., et al. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol. Cancer, 2, 2003, 24.
37. [37] Martin, C.M., Astbury, K., O'Leary, J.J., Molecular profiling of cervical neoplasia. Expert. Rev. Mol. Diagn. 6 (2006), 217–229.
38. [38] Terra, A.P., Murta, E.F., Maluf, P.J., Caballero, O.L., Brait, M., Adad, S.J., Aberrant promoter methylation can be useful as a marker of recurrent disease in patients with cervical intraepithelial neoplasia grade III. Tumori 93 (2007), 572–579.
39. [39] Waxman, A.G., Chelmow, D., Darragh, T.M., Lawson, H., Moscicki, A.B., Revised terminology for cervical histopathology and its implications for management of high-grade squamous intraepithelial lesions of the cervix. Obstet. Gynecol. 120 (2012), 1465–1471.
40. [40] Reuschenbach, M., Clad, A., von Knebel, D.C., Wentzensen, N., Rahmsdorf, J., Schaffrath, F., et al. Performance of p16(INK4a)-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. Gynecol. Oncol., 2010.
41. [41] Nuovo, G.J., Plaia, T.W., Belinsky, S.A., Baylin, S.B., Herman, J.G., In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 12754–12759.
42. [42] von Keyserling, H., Kuhn, W., Schneider, A., Bergmann, T., Kaufmann, A.M., p16INK(4)a and p14ARF mRNA expression in pap smears is age-related. Mod. Pathol. 25 (2012), 465–470.
43. [43] Vazquez-Vega, S., Sanchez-Suarez, L.P., Contreras-Paredes, A., Castellanos-Juarez, E., Penarroja-Flores, R., Lizano-Soberon, M., et al. Nuclear co-expression of p14ARF and p16INK4A in uterine cervical cancer-derived cell lines containing HPV. Cancer Biomark. Sect. A Dis. Mark. 8 (2010), 341–350.
44. [44] Bulten, J., van der Avoort, I.A., Melchers, W.J., Massuger, L.F., Grefte, J.M., Hanselaar, A.G., et al. p14ARF and p16INK4A, two products of the same gene, are differently expressed in cervical intraepithelial neoplasia. Gynecol. Oncol. 101 (2006), 487–494.
45. [45] Wang, J.L., Zheng, B.Y., Li, X.D., Angstrom, T., Lindstrom, M.S., Wallin, K.L., Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin. Cancer Res. 10 (2004), 2407–2414.
46. [46] Schlecht, N.F., Ben-Dayan, M., Anayannis, N., Lleras, R.A., Thomas, C., Wang, Y., et al. Epigenetic changes in the CDKN2A locus are associated with differential expression of P16INK4A and P14ARF in HPV-positive oropharyngeal squamous cell carcinoma. Cancer Med. 4 (2015), 342–353.
47. [47] Sartor, M.A., Dolinoy, D.C., Jones, T.R., Colacino, J.A., Prince, M.E., Carey, T.E., et al. Genome-wide methylation and expression differences in HPV(+) and HPV(−) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics 6 (2011), 777–787.
48. [48] Paz, M.F., Fraga, M.F., Avila, S., Guo, M., Pollan, M., Herman, J.G., et al. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 63 (2003), 1114–1121.
49. [49] Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions triage study (ALTS) group. J. Natl. Cancer Inst. 92 (2000), 397–402.
50. [50] Einstein, M.H., Garcia, F.A., Mitchell, A.L., Day, S.P., Age-stratified performance of the Cervista HPV 16/18 genotyping test in women with ASC-US cytology. Cancer Epidemiol. Biomark. Prev. 20 (2011), 1185–1189.
51. [51] Elit, L.M., Pitfalls in the diagnosis of cervical intraepithelial neoplasia 1. J. Lower Genit. Tract Dis. 8 (2004), 181–187.
52. [52] Kyrgiou, M., Koliopoulos, G., Martin-Hirsch, P., Arbyn, M., Prendiville, W., Paraskevaidis, E., Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367 (2006), 489–498.